Business Description
Boundless Bio Inc
NAICS : 541713
SIC : 2833
ISIN : US10170A1007
Description
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1381.28 | |||||
| Equity-to-Asset | 0.94 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.8 | |||||
| 9-Day RSI | 23.83 | |||||
| 14-Day RSI | 28.65 | |||||
| 3-1 Month Momentum % | -18.89 | |||||
| 6-1 Month Momentum % | -35.01 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.03 | |||||
| Quick Ratio | 17.03 | |||||
| Cash Ratio | 16.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 9.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -40.49 | |||||
| ROIC % | -742.29 | |||||
| ROC (Joel Greenblatt) % | -1456.51 | |||||
| ROCE % | -48.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.23 | |||||
| Price-to-Tangible-Book | 0.23 | |||||
| EV-to-EBIT | 1.87 | |||||
| EV-to-EBITDA | 1.9 | |||||
| EV-to-FCF | 2.17 | |||||
| Price-to-Net-Current-Asset-Value | 0.24 | |||||
| Price-to-Net-Cash | 0.24 | |||||
| Earnings Yield (Greenblatt) % | 53.48 | |||||
| FCF Yield % | -153.71 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BOLD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Boundless Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -14.326 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 28.65 | ||
| 14-Day ATR ($) | 0.170653 | ||
| 20-Day SMA ($) | 2.0745 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 1.7 - 15.24 | ||
| Shares Outstanding (Mil) | 22.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Boundless Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Boundless Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Boundless Bio Inc Frequently Asked Questions
What is Boundless Bio Inc(BOLD)'s stock price today?
The current price of BOLD is $1.72. The 52 week high of BOLD is $15.24 and 52 week low is $1.70.
When is next earnings date of Boundless Bio Inc(BOLD)?
The next earnings date of Boundless Bio Inc(BOLD) is 2025-03-07 Est..
Does Boundless Bio Inc(BOLD) pay dividends? If so, how much?
Boundless Bio Inc(BOLD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers